Pacific Biosciences Of California (PACB) Cash & Equivalents (2010 - 2026)

Pacific Biosciences Of California's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $56.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 3.82% year-over-year to $56.3 million; the TTM figure through Mar 2026 stood at $56.3 million (down 3.82% YoY), while the FY2025 annual figure was $63.7 million, up 15.06% from the prior year.
• Cash & Equivalents was $56.3 million for Q1 2026 at Pacific Biosciences Of California, down from $63.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $428.6 million in Q1 2022 to a low of $54.8 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $182.1 million across 5 years, with a median of $99.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents gained 26.68% in 2023, then slumped 79.78% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $325.1 million in 2022, then tumbled by 44.66% to $179.9 million in 2023, then tumbled by 69.22% to $55.4 million in 2024, then grew by 15.06% to $63.7 million in 2025, then retreated by 11.67% to $56.3 million in 2026.
• The last three Cash & Equivalents figures came in at $56.3 million (Q1 2026), $63.7 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.